Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
1 "HER2 heterogeneity"
Filter
Filter
Article category
Keywords
Publication year
Authors
Review
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
Soomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park
J Pathol Transl Med. 2020;54(1):34-44.   Published online November 6, 2019
DOI: https://doi.org/10.4132/jptm.2019.11.03
  • 18,093 View
  • 1,031 Download
  • 97 Web of Science
  • 99 Crossref
AbstractAbstract PDF
Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is found in about 20% of invasive breast cancers. It is a sole predictive marker for treatment benefits from HER2 targeted therapy and thus, HER2 testing is a routine practice for newly diagnosed breast cancer in pathology. Currently, HER2 immunohistochemistry (IHC) is used for a screening test, and in situ hybridization is used as a confirmation test for HER2 IHC equivocal cases. Since the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines on HER2 testing was first released in 2007, it has been updated to provide clear instructions for HER2 testing and accurate determination of HER2 status in breast cancer. During HER2 interpretation, some pitfalls such as intratumoral HER2 heterogeneity and increase in chromosome enumeration probe 17 signals may lead to inaccurate assessment of HER2 status. Moreover, HER2 status can be altered after neoadjuvant chemotherapy or during metastatic progression, due to biologic or methodologic issues. This review addresses recent updates of ASCO/CAP guidelines and factors complicating in the interpretation of HER2 status in breast cancers.

Citations

Citations to this article as recorded by  
  • Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
    Mariia Ivanova, Francesca Maria Porta, Marianna D’Ercole, Carlo Pescia, Elham Sajjadi, Giulia Cursano, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Elena Guerini-Rocco, Giuseppe Curigliano, Giuseppe Viale, Nicola Fusco
    Virchows Archiv.2024; 484(1): 3.     CrossRef
  • Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing–Based Comprehensive Tumor Profiling in Liquid Biopsy Samples
    Johannes Harter, Eleonora Buth, Janina Johaenning, Florian Battke, Maria Kopp, Henning Zelba, Martin Schulze, Jiri Koedding, Saskia Biskup
    The Journal of Molecular Diagnostics.2024; 26(1): 61.     CrossRef
  • Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
    Camille Suydam, Fairouz Chibane, Nicole Brown, Madeleine Schlafly, Alicia H. Arnold, Intisar Ghleilib, Melissa Easley, Joseph White
    Annals of Surgical Oncology.2024; 31(1): 376.     CrossRef
  • Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis
    Huiyue Li, Jennifer K. Plichta, Kan Li, Yizi Jin, Samantha M. Thomas, Fei Ma, Li Tang, Qingyi Wei, You-Wen He, Qichen Chen, Yuanyuan Guo, Yueping Liu, Jian Zhang, Sheng Luo
    Breast Cancer Research and Treatment.2024; 204(1): 89.     CrossRef
  • Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer
    Jennifer L. Guerriero, Jia-Ren Lin, Ricardo G. Pastorello, Ziming Du, Yu-An Chen, Madeline G. Townsend, Kenichi Shimada, Melissa E. Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L. Taneja, Otto Metzger, Sara M. Tol
    npj Breast Cancer.2024;[Epub]     CrossRef
  • Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer
    Melissa Yuwono Tjota, Jeremy P Segal, Peng Wang
    The Journal of Applied Laboratory Medicine.2024; 9(1): 76.     CrossRef
  • High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles
    Sanathana Konugolu Venkata Sekar, Hui Ma, Katarzyna Komolibus, Gokhan Dumlupinar, Matthias J. Mickert, Krzysztof Krawczyk, Stefan Andersson-Engels
    Biomedical Optics Express.2024; 15(2): 900.     CrossRef
  • HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study
    Ximena Baez-Navarro, Mieke R. van Bockstal, Agnes Jager, Carolien H.M. van Deurzen
    Pathology.2024; 56(3): 334.     CrossRef
  • Fast-tracking drug development with biomarkers and companion diagnostics
    Noreen McBrearty, Devika Bahal, Suso Platero
    Journal of Cancer Metastasis and Treatment.2024;[Epub]     CrossRef
  • Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression
    Gary Tozbikian, Savitri Krishnamurthy, Marilyn M. Bui, Michael Feldman, David G. Hicks, Shabnam Jaffer, Thaer Khoury, Shi Wei, Hannah Wen, Paula Pohlmann
    Archives of Pathology & Laboratory Medicine.2024; 148(2): 242.     CrossRef
  • Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer
    Eliya Farah, Chantelle Carbonell, Devon J. Boyne, Darren R. Brenner, Jan-Willem Henning, Daniel Moldaver, Simran Shokar, Winson Y. Cheung
    Cancers.2024; 16(3): 518.     CrossRef
  • Clinical Internal Dosimetry and Biodistribution of 177Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma
    Yoga S. Narwadkar, Rahul V. Parghane, Sudeep Sahu, Sangita Lad, Kamal Deep, Gaurav Wanage, Tejal Suralkar, Sharmila Banerjee, Sudeep Gupta, Sandip Basu, Rajendra A. Badwe
    Clinical Nuclear Medicine.2024; 49(4): e149.     CrossRef
  • Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration
    Cristina Díaz del Arco, María Jesús Fernández Aceñero, Luis Ortega Medina
    International Journal of Molecular Sciences.2024; 25(5): 2649.     CrossRef
  • The combined immunohistochemical expression of AMBRA1 and SQSTM1 identifies patients with poorly differentiated cutaneous squamous cell carcinoma at risk of metastasis: A proof of concept study
    Michael H. Alexander, William J. Cousins, Tom Ewen, Andrew P. South, Penny Lovat, Niki Stefanos
    Journal of Cutaneous Pathology.2024;[Epub]     CrossRef
  • Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry
    Jing Wang, Esther Yoon, Savitri Krishnamurthy
    Annals of Diagnostic Pathology.2024; 70: 152288.     CrossRef
  • Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial
    Lingzhou Zhao, Yan Xing, Changcun Liu, Shaofei Ma, Wenhua Huang, Zhen Cheng, Jinhua Zhao
    Breast Cancer Research.2024;[Epub]     CrossRef
  • Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients
    Yibo Chen, Tianyi Zhang, Rui Zhang, Xuchen Cao
    Cancer Biotherapy and Radiopharmaceuticals.2024;[Epub]     CrossRef
  • Surgical Management of the Axilla in HR+/HER2– Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database
    Vayda R. Barker, Samer A. Naffouje, Melissa A. Mallory, Susan A. Hoover, Christine Laronga
    Annals of Surgical Oncology.2023; 30(13): 8371.     CrossRef
  • Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer
    Yuan Guo, Xiaotong Xie, Wenjie Tang, Siyi Chen, Mingyu Wang, Yaheng Fan, Chuxuan Lin, Wenke Hu, Jing Yang, Jialin Xiang, Kuiming Jiang, Xinhua Wei, Bingsheng Huang, Xinqing Jiang
    European Radiology.2023; 34(2): 899.     CrossRef
  • Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
    Lan Deng, Le Zhao, Lifen Liu, Haomin Huang
    Open Life Sciences.2023;[Epub]     CrossRef
  • HER2-low expression in patients with advanced or metastatic solid tumors
    B. Uzunparmak, C. Haymaker, G. Raso, S. Masciari, L. Wang, H. Lin, A. Gorur, B. Kirby, A.-M. Cimo, A. Kennon, Q. Ding, G. Urschel, Y. Yuan, G. Feng, Y. Rizvi, A. Hussain, C. Zhu, P. Kim, G. Abbadessa, V. Subbiah, T.A. Yap, J. Rodon, S.A. Piha-Paul, F. Mer
    Annals of Oncology.2023; 34(11): 1035.     CrossRef
  • Data on 2D culture characterisation of potential markers in human HER2-positive breast cancer cell lines
    Son H. Pham, Lyn R. Griffiths, Rachel K. Okolicsanyi, Larisa M. Haupt
    Data in Brief.2023; 46: 108880.     CrossRef
  • Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
    Christiane Palm, Catherine E. Connolly, Regina Masser, Barbara Padberg Sgier, Eva Karamitopoulou, Quentin Simon, Beata Bode, Marianne Tinguely
    Diagnostics.2023; 13(1): 168.     CrossRef
  • Gene amplification mutations originate prior to selective stress in Acinetobacter baylyi
    Jennifer A Herrmann, Agata Koprowska, Tesa J Winters, Nancy Villanueva, Victoria D Nikityuk, Feini Pek, Elizabeth M Reis, Constancia Z Dominguez, Daniel Davis, Eric McPherson, Staci R Rocco, Cynthia Recendez, Shyla M Difuntorum, Kelly Faeth, Mario D Lopez
    G3.2023;[Epub]     CrossRef
  • Flow Rate-Independent Multiscale Liquid Biopsy for Precision Oncology
    Jie Wang, Robert Dallmann, Renquan Lu, Jing Yan, Jérôme Charmet
    ACS Sensors.2023; 8(3): 1200.     CrossRef
  • Single-cell HER2 quantification via instant signal amplification in microdroplets
    Xiaoxian Liu, Yifan Zhu, Caoxin Li, Yanyun Fang, Jinna Chen, Fei Xu, Yanqing Lu, Perry Ping Shum, Ying Liu, Guanghui Wang
    Analytica Chimica Acta.2023; 1251: 340976.     CrossRef
  • Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
    Daniela Miladinova
    Frontiers in Molecular Biosciences.2023;[Epub]     CrossRef
  • CORRELATION BETWEEN DIFFERENT CLINICOPATHOLOGICAL PARAMETERS AND MOLECULAR SUBTYPES OF FEMALE BREAST CARCINOMA IN SOUTH REGION OF IRAQ
    Yassir Alaa Muhammed Hassan Shubbar
    Wiadomości Lekarskie.2023; 76(1): 97.     CrossRef
  • Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test
    Elham Sajjadi, Elena Guerini-Rocco, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Mariia Ivanova, Nicola Fusco
    Frontiers in Molecular Biosciences.2023;[Epub]     CrossRef
  • Protective Effect of HER2 Gene Polymorphism rs24537331 in the Outcome of Canine Mammary Tumors
    Ana Canadas-Sousa, Marta Santos, Patrícia Dias-Pereira
    Animals.2023; 13(8): 1384.     CrossRef
  • Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review
    Jin Wang, Dongying Liao, Xuemin Zhang, Changhong Miao, Kuang Chen
    Breast Cancer: Targets and Therapy.2023; Volume 15: 281.     CrossRef
  • HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
    Marina Popović, Tajana Silovski, Marija Križić, Natalija Dedić Plavetić
    International Journal of Molecular Sciences.2023; 24(9): 8206.     CrossRef
  • HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast
    Aditya Bardia, Giuseppe Viale
    Targeted Oncology.2023; 18(3): 313.     CrossRef
  • Histopathological and immunohistochemical analysis of predictive and prognostic markers in spontaneous canine mammary cancer
    Vladimír Tancoš, Marcel Kovalik, Martin Levkut, Martina Bobrovská, Petra Kolenčíková, Ľubomír Straka, Zuzana Ševčíková, Ondřej Škor, Martina Antošová, Lukáš Plank, Keith L. Thoday
    Acta Veterinaria Brno.2023; 92(2): 143.     CrossRef
  • Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study
    Timothy Qi, Yanguang Cao
    European Journal of Pharmaceutical Sciences.2023; 186: 106467.     CrossRef
  • The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis
    Yakup Ergun, Baran Akagunduz, Cengiz Karacin, Sema Turker, Gokhan Ucar
    Clinical Breast Cancer.2023; 23(6): 567.     CrossRef
  • Efficacy, toxicity and prognostic factors of pyrotinib‑involved neoadjuvant therapy in HER2‑positive breast cancer: A retrospective study
    Hao Wang, Hailing Cao, Zhiyun Guo
    Oncology Letters.2023;[Epub]     CrossRef
  • Identification of novel chemical scaffolds against kinase domain of cancer causing human epidermal growth factor receptor 2: a systemic chemoinformatic approach
    Faris Alrumaihi
    Journal of Biomolecular Structure and Dynamics.2023; : 1.     CrossRef
  • Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
    Feng Ye, Saikat Dewanjee, Yuehua Li, Niraj Kumar Jha, Zhe-Sheng Chen, Ankush Kumar, Vishakha, Tapan Behl, Saurabh Kumar Jha, Hailin Tang
    Molecular Cancer.2023;[Epub]     CrossRef
  • Weakly supervised bilayer convolutional network in segmentation of HER2 related cells to guide HER2 targeted therapies
    Ching-Wei Wang, Kun-Lin Lin, Hikam Muzakky, Yi-Jia Lin, Tai-Kuang Chao
    Computerized Medical Imaging and Graphics.2023; 108: 102270.     CrossRef
  • Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
    Francesca Maria Porta, Elham Sajjadi, Konstantinos Venetis, Chiara Frascarelli, Giulia Cursano, Elena Guerini-Rocco, Nicola Fusco, Mariia Ivanova
    Journal of Personalized Medicine.2023; 13(7): 1176.     CrossRef
  • HER2 Equivocal (Score = 2+) Breast Carcinoma Cases Identified by Immunohistochemistry at a South African Hospital. What is the Impact of Fluorescent In Situ Hybridization Testing?
    Reena Dhansukh Mohanlal, Nikki Bouwer, Pascale Willem
    Applied Immunohistochemistry & Molecular Morphology.2023; 31(8): 555.     CrossRef
  • Discordance of HER2 Expression and/or Amplification on Repeat Testing
    Timothy P. DiPeri, Kathleen Kong, Kaushik Varadarajan, Daniel D. Karp, Jaffer A. Ajani, Shubham Pant, Michael F. Press, Sarina A. Piha-Paul, Ecaterina E. Dumbrava, Funda Meric-Bernstam
    Molecular Cancer Therapeutics.2023; 22(8): 976.     CrossRef
  • Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes
    Mariausilia Franchina, Cristina Pizzimenti, Vincenzo Fiorentino, Maurizio Martini, Giuseppina Rosaria Rita Ricciardi, Nicola Silvestris, Antonio Ieni, Giovanni Tuccari
    International Journal of Molecular Sciences.2023; 24(16): 12795.     CrossRef
  • Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
    Kuikui Jiang, Danyang Zhou, Fei Xu, Wen Xia, Qiufan Zheng, Qianyi Lu, Rongzhen Luo, Ruoxi Hong, Shusen Wang
    BMC Cancer.2023;[Epub]     CrossRef
  • Single domain antibodies specific for HER2 dimerization domain effectively disrupts HER2 dimerization
    Ahmad Najafi, Reza Valadan, Hossein Asgarian-Omran, Alireza Rafiei, Mohsen Tehrani
    International Immunopharmacology.2023; 124: 110999.     CrossRef
  • Récepteur du facteur de croissance épidermique HER2, tests utilisés pour rechercher son amplification dans le cancer du sein : principes et limites
    Imane Eliahiai, Mohammed Eljiar, Sanae Chaib, Jinane KHarmoum, Mariame Chraïbi
    Bulletin du Cancer.2023; 110(12): 1301.     CrossRef
  • HER2 copy number determination in breast cancer using the highly sensitive droplet digital PCR method
    Beate Alinger-Scharinger, Cornelia Kronberger, Georg Hutarew, Wolfgang Hitzl, Roland Reitsamer, Klaassen-Federspiel Frederike, Martina Hager, Thorsten Fischer, Karl Sotlar, Heidi Jaksch-Bogensperger
    Virchows Archiv.2023;[Epub]     CrossRef
  • Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS)
    Jean-Louis Merlin, Marie Husson, Nassim Sahki, Pauline Gilson, Vincent Massard, Alexandre Harlé, Agnès Leroux
    Biomedicines.2023; 11(12): 3164.     CrossRef
  • Design of a Ratiometric Plasmonic Biosensor for Herceptin Detection in HER2-Positive Breast Cancer
    Neda Shahbazi, Rouholah Zare-Dorabei, Seyed Morteza Naghib
    ACS Biomaterials Science & Engineering.2022; 8(2): 871.     CrossRef
  • A highly sensitive nanobiosensor based on aptamer-conjugated graphene-decorated rhodium nanoparticles for detection of HER2-positive circulating tumor cells
    Mahdi Sadeghi, Soheila Kashanian, Seyed Morteza Naghib, Esfandyar Askari, Fateme Haghiralsadat, Davood Tofighi
    Nanotechnology Reviews.2022; 11(1): 793.     CrossRef
  • Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
    Carrie S. Wynn, Shou-Ching Tang
    Cancer and Metastasis Reviews.2022; 41(1): 193.     CrossRef
  • Electroanalytical overview: screen-printed electrochemical sensing platforms for the detection of vital cardiac, cancer and inflammatory biomarkers
    Robert D. Crapnell, Alejandro Garcia-Miranda Ferrari, Nina C. Dempsey, Craig E. Banks
    Sensors & Diagnostics.2022; 1(3): 405.     CrossRef
  • FTO genotype was associated with breast cancer in HER2 negative patients
    Fateme Montazeri, Hossein Hatami, Soroor Fathi, Naeemeh Hasanpour Ardekanizadeh, Fatemeh Bourbour, Samira Rastgoo, Fatemeh Shafiee, Mohammad Esmail Akbari, Maryam Gholamalizadeh, Seyed Alireza Mosavi Jarrahi, Saeid Doaei
    Clinical Nutrition ESPEN.2022; 49: 495.     CrossRef
  • Breast Cancer Human Epidermal Growth Factor Receptor 2 mRNA Molecular Testing Compared to Immunohistochemistry with Correlation to Neoadjuvant Therapy Response
    Mahmoud Behairy, Samia Mohamed Gabal, Mohamed Sherif Negm
    Open Access Macedonian Journal of Medical Sciences.2022; 10(A): 352.     CrossRef
  • Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review
    Noortje Verschoor, Teoman Deger, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W.M. Martens
    Cancer Treatment Reviews.2022; 106: 102384.     CrossRef
  • Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients
    Hui Liu, Xiaoyan Hu, Lingyun Wang, Tao Du, Jing Feng, Ming Li, Lei Liu, Xiaofang Liu
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Use of Radionuclide-Based Imaging Methods in Breast Cancer
    Betül Altunay, Agnieszka Morgenroth, Felix M. Mottaghy
    Seminars in Nuclear Medicine.2022; 52(5): 561.     CrossRef
  • Functional regulations between genetic alteration-driven genes and drug target genes acting as prognostic biomarkers in breast cancer
    Li Wang, Lei Yu, Jian Shi, Feng Li, Caiyu Zhang, Haotian Xu, Xiangzhe Yin, Lixia Wang, Shihua Lin, Anastasiia Litvinova, Yanyan Ping, Shangwei Ning, Hongying Zhao
    Scientific Reports.2022;[Epub]     CrossRef
  • Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
    Anastasia Alataki, Mitch Dowsett
    Endocrine-Related Cancer.2022; 29(8): R105.     CrossRef
  • The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
    Olga D. Bragina, Sergei M. Deyev, Vladimir I. Chernov, Vladimir M. Tolmachev
    Acta Naturae.2022; 14(2): 4.     CrossRef
  • Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations
    Stephanie E. Siegmund, Danielle K. Manning, Phani K. Davineni, Fei Dong
    Modern Pathology.2022; 35(10): 1458.     CrossRef
  • Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
    Matti Aapro, Fatima Cardoso, Giuseppe Curigliano, Alexandru Eniu, Joseph Gligorov, Nadia Harbeck, Andreas Mueller, Olivia Pagani, Shani Paluch-Shimon, Elzbieta Senkus, Beat Thürlimann, Khalil Zaman
    The Breast.2022; 66: 145.     CrossRef
  • Application of Fluorescence In Situ Hybridization Assisted by Fluorescence Microscope in Detection of Her2 Gene in Breast Cancer Patients
    Fang Lu, Tingting Zhou, Yan Liu, Liying Song, Bin Zhang, Yuyan Li, Sorayouth Chumnanvej
    Contrast Media & Molecular Imaging.2022; 2022: 1.     CrossRef
  • High sensitivity label-free detection of HER2 using an Al–GaN/GaN high electron mobility transistor-based biosensor
    Shivanshu Mishra, Pharyanshu Kachhawa, Amber Kumar Jain, Rajiv Ranjan Thakur, Nidhi Chaturvedi
    Lab on a Chip.2022; 22(21): 4129.     CrossRef
  • Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines
    B. R. Nagarjun, Biren Parikh, Manaswi Nareshkumar Patel, Pina J. Trivedi, Dharmesh M. Patel
    South Asian Journal of Cancer.2022; 11(04): 281.     CrossRef
  • S‑phase fraction, lymph node status and disease staging as the main prognostic factors to differentiate between young and older patients with invasive breast carcinoma
    António Pinto, João Matos, Teresa Pereira, Giovani Silva, Saudade André
    Oncology Letters.2022;[Epub]     CrossRef
  • Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling
    Alina Batzilla, Junyan Lu, Jarno Kivioja, Kerstin Putzker, Joe Lewis, Thorsten Zenz, Wolfgang Huber, James Gallo
    PLOS Computational Biology.2022; 18(8): e1010438.     CrossRef
  • Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
    O. D. Bragina, V. I. Chernov, S. M. Deyev, V. M. Tolmachev
    Bulletin of Siberian Medicine.2022; 21(3): 132.     CrossRef
  • Molecular Pathology of Gastric Cancer
    Moonsik Kim, An Na Seo
    Journal of Gastric Cancer.2022; 22(4): 264.     CrossRef
  • Loss of NECTIN1 triggers melanoma dissemination upon local IGF1 depletion
    Julien Ablain, Amira Al Mahi, Harriet Rothschild, Meera Prasad, Sophie Aires, Song Yang, Maxim E. Dokukin, Shuyun Xu, Michelle Dang, Igor Sokolov, Christine G. Lian, Leonard I. Zon
    Nature Genetics.2022; 54(12): 1839.     CrossRef
  • Advanced diagnosis technologies for HER2 breast cancer markers
    Mengxue Zhang
    Highlights in Science, Engineering and Technology.2022; 14: 44.     CrossRef
  • An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
    Aleix Prat, Aditya Bardia, Giuseppe Curigliano, M. Elizabeth H. Hammond, Sibylle Loibl, Sara M. Tolaney, Giuseppe Viale
    JAMA Oncology.2022; 8(11): 1676.     CrossRef
  • Development of T-cell engagers selective for cells co-expressing two antigens
    Danielle M. Dicara, Sunil Bhakta, Mary Ann Go, James Ziai, Ron Firestein, Bill Forrest, Chen Gu, Steven R. Leong, Genee Lee, Shang-Fan Yu, Andrew G. Polson, Nicholas J. Agard
    mAbs.2022;[Epub]     CrossRef
  • The clinical significance of HER2 expression in DCIS
    Ioanna Akrida, Francesk Mulita
    Medical Oncology.2022;[Epub]     CrossRef
  • Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
    Rachel Occhiogrosso Abelman, Arielle Medford, Laura Spring, Aditya Bardia
    The Cancer Journal.2022; 28(6): 423.     CrossRef
  • The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients
    Ugur Gezer, Abel J. Bronkhorst, Stefan Holdenrieder
    Diagnostics.2022; 12(12): 3042.     CrossRef
  • Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
    Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li
    Systematic Reviews.2022;[Epub]     CrossRef
  • Interactions dietary components with expression level of breast cancer-related genes
    Fatemeh Bourbour, Azam Pourtaheri, Khadijeh Abbasi, Naeemeh Hasanpour Ardekanizadeh, Maryam Gholamalizadeh, Azadeh Hajipour, Sepideh Abdollahi, Seyedeh Elaheh Bagheri, Mina Ahmadzadeh, Saeid Doaei, Arezoo Haghighian
    Egyptian Journal of Medical Human Genetics.2022;[Epub]     CrossRef
  • HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging
    Betül Altunay, Agnieszka Morgenroth, Mohsen Beheshti, Andreas Vogg, Nicholas C. L. Wong, Hong Hoi Ting, Hans-Jürgen Biersack, Elmar Stickeler, Felix M. Mottaghy
    European Journal of Nuclear Medicine and Molecular Imaging.2021; 48(5): 1371.     CrossRef
  • Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
    Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart
    Cancer Treatment Reviews.2021; 99: 102229.     CrossRef
  • Histologic Patterns of Cutaneous Metastases of Breast Carcinoma: A Clinicopathologic Study of 232 Cases
    Shira Ronen, David Suster, Wei-Shen Chen, Natali Ronen, Sri Krishna C. Arudra, Celestine Trinidad, Doina Ivan, Victor G. Prieto, Saul Suster
    The American Journal of Dermatopathology.2021; 43(6): 401.     CrossRef
  • Standardized pathology report for breast cancer
    Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
    Journal of Pathology and Translational Medicine.2021; 55(1): 1.     CrossRef
  • The impact of oral contraceptive use on breast cancer risk: State of the art and future perspectives in the era of 4P medicine
    R. Bonfiglio, M.L. Di Pietro
    Seminars in Cancer Biology.2021; 72: 11.     CrossRef
  • The Co-Expression of Melanoma-Antigen Family a Proteins and New York Esophageal Squamous Cell Carcinoma-1 in Breast Cancer: A Pilot Study
    Yu-Xin Wang, Feng-Lian Li, Li-Xin Du, Jun-Fang Liu, Li-Gang Huo, Shu-Qing Li, Bin Tian
    Cancer Management and Research.2021; Volume 13: 6123.     CrossRef
  • Targeting HER2 protein in individual cells using ICP-MS detection and its potential as prognostic and predictive breast cancer biomarker
    A. Fernández Asensio, M. Corte-Rodríguez, J. Bettmer, L.M. Sierra, M. Montes-Bayón, E. Blanco- González
    Talanta.2021; 235: 122773.     CrossRef
  • Development of a 99mTc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer
    Lingzhou Zhao, Changcun Liu, Yan Xing, Jin He, Jim O’Doherty, Wenhua Huang, Jinhua Zhao
    Molecular Pharmaceutics.2021; 18(9): 3616.     CrossRef
  • WITHDRAWN: Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
    Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan
    Bulletin du Cancer.2021;[Epub]     CrossRef
  • Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
    Emad A. Rakha, Islam M. Miligy, Cecily M. Quinn, Elena Provenzano, Abeer M. Shaaban, Caterina Marchiò, Michael S. Toss, Grace Gallagy, Ciara Murray, Janice Walshe, Ayaka Katayama, Karim Eldib, Nahla Badr, Bruce Tanchel, Rebecca Millican-Slater, Colin Purd
    British Journal of Cancer.2021; 124(11): 1836.     CrossRef
  • Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes
    Catherine L. Wetzel, Thomas L. Sutton, Stuart Gardiner, Maryam Farinola, Nathalie Johnson, Jennifer R. Garreau
    Journal of Surgical Oncology.2021; 124(8): 1224.     CrossRef
  • Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy
    Lun Li, Min Chen, Shuyue Zheng, Hanlu Li, Weiru Chi, Bingqiu Xiu, Qi Zhang, Jianjing Hou, Jia Wang, Jiong Wu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • tRNA‐derived fragments: tRF‐Gly‐CCC‐046, tRF‐Tyr‐GTA‐010 and tRF‐Pro‐TGG‐001 as novel diagnostic biomarkers for breast cancer
    Yue Zhang, Zhao Bi, Xiaohan Dong, Miao Yu, Kangyu Wang, Xingguo Song, Li Xie, Xianrang Song
    Thoracic Cancer.2021; 12(17): 2314.     CrossRef
  • Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3
    L. De Cock, J. Heylen, A. Wildiers, K. Punie, A. Smeets, C. Weltens, P. Neven, J. Billen, A. Laenen, H. Wildiers
    ESMO Open.2021; 6(4): 100203.     CrossRef
  • Standardized Pathology Report for Breast Cancer
    Soo Youn Cho, So Yeon Park, Young Kyung Bae, Jee Yeon Kim, Eun Kyung Kim, Woo Gyeong Kim, Youngmee Kwon, Ahwon Lee, Hee Jin Lee, Ji Shin Lee, Jee Young Park, Gyungyub Gong, Hye Kyoung Yoon
    Journal of Breast Cancer.2021; 24(1): 1.     CrossRef
  • Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198
    Jin-xiu Zhong, Yun-yuan Kong, Rong-guang Luo, Guo-jin Xia, Wen-xing He, Xue-zhong Chen, Wei-wei Tan, Qing-jie Chen, Yu-yin Huang, Yan-xing Guan
    Journal of Translational Medicine.2021;[Epub]     CrossRef
  • Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
    Benoîte Mery, Philippe Toussaint, Pierre-Etienne Heudel, Armelle Dufresne, Mélodie Carbonnaux, Hélène Vanacker, Thomas Bachelot, Olivier Trédan
    Bulletin du Cancer.2021; 108(11): 11S8.     CrossRef
  • HER2 alterations in non-small-cell lung cancer – Druggable or undruggable?
    SureshKumar Bondili, Ravindra Nandhana, Vanita Noronha, Swayamprabha Pawar, Nandini Menon, Omshree Shetty, Anuradha Chougule, Abhishek Mahajan, Rajiv Kumar, VijayM Patil, Amit Joshi, Kumar Prabhash
    Cancer Research, Statistics, and Treatment.2021; 4(2): 374.     CrossRef
  • UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer
    Evgenii L. Guryev, Anita S. Smyshlyaeva, Natalia Y. Shilyagina, Evgeniya A. Sokolova, Samah Shanwar, Alexey B. Kostyuk, Alexander V. Lyubeshkin, Alexey A. Schulga, Elena V. Konovalova, Quan Lin, Indrajit Roy, Irina V. Balalaeva, Sergey M. Deyev, Andrei V.
    Molecules.2020; 25(18): 4302.     CrossRef
  • Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
    Min Chong Kim, Su Hwan Kang, Jung Eun Choi, Young Kyung Bae
    Journal of Breast Cancer.2020; 23(5): 484.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine